In Vitro Evaluation of the Activity of Imipenem-Relebactam against 451 Recent Clinical Isolates of Bacteroides Group and Related Species

David R Snydman; Nilda V Jacobus; Laura A McDermott

doi:10.1128/AAC.01125-16

In Vitro Evaluation of the Activity of Imipenem-Relebactam against 451 Recent Clinical Isolates of Bacteroides Group and Related Species

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6393-7. doi: 10.1128/AAC.01125-16. Print 2016 Oct.

Authors

David R Snydman¹, Nilda V Jacobus², Laura A McDermott²

Affiliations

¹ Department of Medicine, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA dsnydman@tuftsmedicalcenter.org.
² Department of Medicine, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA.

Abstract

We evaluated the in vitro activity of imipenem-relebactam (imipenem-MK7655) against 451 recent clinical isolates within the Bacteroides group and related species. Relebactam did not enhance or inhibit the activity of imipenem against Bacteroides fragilis or other Bacteroides species. No synergistic or antagonistic effect was observed. The MICs of imipenem-relebactam were equal to or within one dilution of the MICs of these isolates to imipenem.

Publication types

Multicenter Study

MeSH terms

Anti-Bacterial Agents / pharmacology*
Azabicyclo Compounds / pharmacology*
Bacteroides / drug effects*
Bacteroides / isolation & purification
Drug Synergism
Humans
Imipenem / pharmacology*
Microbial Sensitivity Tests

Substances

Anti-Bacterial Agents
Azabicyclo Compounds
Imipenem
relebactam

Grants and funding

This work was funded by a grant from Merck and Company to Tufts Medical Center.